Evolent Health, Inc. provided earnings guidance for the fiscal year 2023. For the period, the company expects revenue growth to exceed 25% before any impact from NIA, equating to organic growth of 20%+ and the contribution of seven months of incremental revenue from the IPG acquisition, completed in August.